We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Effect of Lamivudine Therapy on the Serum Covalently Closed-Circular (ccc) DNA of Chronic Hepatitis B Infection.
- Authors
Yuen, Man-Fung; Wong, Danny Ka-Ho; Sum, Simon Siu-Man; Yuan, He-Jun; Yuen, John Chi-Hang; Chan, Annie On-On; Wong, Benjamin Chun-Yu; Lai, Ching-Lung
- Abstract
OBJECTIVE: To determine the effect of 1-yr lamivudine treatment on serum covalently closed-circular DNA (cccDNA) level.PATIENTS AND METHOD: Serum total HBV DNA and cccDNA levels at baseline, week 24, and week 52 were measured in 82 lamivudine-treated patients, 17 of whom received 1-yr placebo and acted as controls.RESULTS: There was a significant reduction in the cccDNA levels from baseline (median 3.0× 106 copies/ml) to week 24 (33,476 copies/ml) and week 52 (48,694 copies/ml) (p<0.001 for both). The median reduction in cccDNA level at week 24 and 52 were 2.21 and 2.12 logs, respectively, which were significantly greater than those of controls (0.31 log,p<0.001; 0.2 log,p<0.001, respectively). Fifteen patients (18.3%) developed YMDD mutations by week 52. Compared to patients without YMDD mutations, patients with YMDD mutations had significantly less median reduction of total HBV DNA level (4.44vs3.65 logs, respectively,p= 0.02) and cccDNA level (2.27vs1.65 logs, respectively,p= 0.016) at week 24 and significantly less median reduction of cccDNA at week 52 (2.35vs0.8 logs respectively,p<0.001).CONCLUSIONS: One-year lamivudine treatment decreased serum cccDNA level by 2 logs. The chance of YMDD mutations at week 52 was related to the magnitude of viral suppression at week 24.(Am J Gastroenterol 2005;100:1099–1103)
- Subjects
DRUGS; SERUM; DNA; PLACEBOS; PATIENTS; MEDICAL care
- Publication
American Journal of Gastroenterology (Springer Nature), 2005, Vol 100, Issue 5, p1099
- ISSN
0002-9270
- Publication type
Article
- DOI
10.1111/j.1572-0241.2005.41530.x